Risk Factors for Breast Cancer-Related Lymphedema, Risk Reduction, and Myths about Precautionary Behaviors

[1] Naoum GE(2020)Quantifying the impact of axillary surgery and nodal irradiation on breast cancer–related lymphedema and local tumor control: long-term results from a prospective screening trial J Clin Oncol 38 3430-3438

[2] Roberts S(2021)Risk of lymphedema following contemporary treatment for breast cancer: an analysis of 7617 consecutive patients from a multidisciplinary perspective Ann surg 274 170-178

[3] Brunelle CL(2013)Pathophysiology of lymphedema Seminars in Oncol Nurs 29 4-11

[4] Byun HK(2021)The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment NPJ Breast Cancer 7 70-21

[5] Chang JS(2017)Diagnostic methods, risk factors, prevention, and management of breast cancer-related lymphedema: past, present, and future directions Curr Breast Cancer Rep 9 111-2826

[6] Im SH(2017)Considerations for clinicians in the diagnosis, prevention, and treatment of breast cancer-related lymphedema: recommendations from a multidisciplinary expert ASBrS panel: part 1: definitions, assessments, education, and future directions Ann Surg Oncol 24 2818-515

[7] Ridner SH(2013)Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis Lancet Oncol 14 500-432

[8] Jørgensen MG(2010)Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastasis: the American College of Surgeons Oncology Group Z0011 Ann Surg 252 426-3663

[9] Toyserkani NM(2007)Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011 J Clin Oncol 25 3657-1461

[10] Hansen FG(2013)Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial JAMA 310 1455-1310

[1] Naoum GE(2020)Quantifying the impact of axillary surgery and nodal irradiation on breast cancer–related lymphedema and local tumor control: long-term results from a prospective screening trial J Clin Oncol 38 3430-3438

[2] Roberts S(2021)Risk of lymphedema following contemporary treatment for breast cancer: an analysis of 7617 consecutive patients from a multidisciplinary perspective Ann surg 274 170-178

[3] Brunelle CL(2013)Pathophysiology of lymphedema Seminars in Oncol Nurs 29 4-11

[4] Byun HK(2021)The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment NPJ Breast Cancer 7 70-21

[5] Chang JS(2017)Diagnostic methods, risk factors, prevention, and management of breast cancer-related lymphedema: past, present, and future directions Curr Breast Cancer Rep 9 111-2826

[6] Im SH(2017)Considerations for clinicians in the diagnosis, prevention, and treatment of breast cancer-related lymphedema: recommendations from a multidisciplinary expert ASBrS panel: part 1: definitions, assessments, education, and future directions Ann Surg Oncol 24 2818-515

[7] Ridner SH(2013)Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis Lancet Oncol 14 500-432

[8] Jørgensen MG(2010)Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastasis: the American College of Surgeons Oncology Group Z0011 Ann Surg 252 426-3663

[9] Toyserkani NM(2007)Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011 J Clin Oncol 25 3657-1461

[10] Hansen FG(2013)Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial JAMA 310 1455-1310